Literature DB >> 15919492

Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice.

J J Naoum1, K J Woodside, S Zhang, P G Rychahou, G C Hunter.   

Abstract

Because of its antiproliferative properties and its known effects on plasma lipids, we evaluated the mechanisms underlying the effect of rapamycin (RPM) on endothelial nitric oxide synthase (eNOS) and matrix metalloproteinases in Apo-E knockout mice. Apo-E-/- mice fed a high-cholesterol diet were given RPM (3 mg/kg per day intraperitoneally) or no treatment for 10 weeks (n = 8 each). Blood was drawn for serum lipid analysis. Protein was extracted from the abdominal aortas for Western immunoblotting and zymography. Cellular localization was assessed by histology and immunohistochemistry. The data, expressed as mean +/- SEM, were compared by Student's t test or analysis of variance (ANOVA). Lipid levels at 10 weeks were similar in both groups except for higher triglyceride levels in RPM-treated animals. RPM-treated mice expressed greater amounts of eNOS and p-eNOS compared with controls (P < .05). Akt, p-Akt, Caveolin-1, and p-Caveolin-1 were not significantly affected by RPM treatment. RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression. The increased expression and phosphorylation of eNOS with RPM appears to be regulated by mechanisms other than Akt or Caveolin-1. Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919492     DOI: 10.1016/j.transproceed.2005.02.080

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.

Authors:  Ernesto Paoletti; Franco Citterio; Alberto Corsini; Luciano Potena; Paolo Rigotti; Silvio Sandrini; Elisabetta Bussalino; Giovanni Stallone
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

2.  Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels.

Authors:  Wen Qiang Chen; Lin Zhong; Lei Zhang; Xiao Ping Ji; Mei Zhang; Yu Xia Zhao; Cheng Zhang; Yun Zhang
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

3.  M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.

Authors:  Subrata Chakrabarti; Lea M Beaulieu; Lara A Reyelt; Mark D Iafrati; Jane E Freedman
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

4.  Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.

Authors:  L Zhao; T Ding; T Cyrus; Y Cheng; H Tian; M Ma; R Falotico; D Praticò
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

5.  Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation.

Authors:  You-Lin Tain; Veronika Muller; Attila J Szabo; Aaron Erdely; Cheryl Smith; Chris Baylis
Journal:  Nitric Oxide       Date:  2007-10-12       Impact factor: 4.427

6.  Rapamune does not attenuate high cholesterol-induced atherosclerosis in rabbits.

Authors:  Ahmed Attia; Mohamed Ahmed; Siew Hon Ng; Kailash Prasad; Ahmed Shoker
Journal:  Int J Angiol       Date:  2014-06

Review 7.  Potential therapeutic effects of mTOR inhibition in atherosclerosis.

Authors:  Ammar Kurdi; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

8.  Effect of sirolimus on carotid atherosclerosis in kidney transplant recipients: data derived from a prospective randomized controlled trial.

Authors:  Andre L Silva; Daniéliso R Fusco; Hong S Nga; Henrique M Takase; Ariane M Bravin; Mariana M Contti; Mariana F Valiatti; Luis Gustavo M de Andrade
Journal:  Clin Kidney J       Date:  2018-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.